HK reg	Actual Medicinal Product
51979	Ancobon (5-flucytosine) oral capsule 500 mg
41418	Acyclovir Stada (acyclovir) topical cream 5 %
47049	Zovirax Cold Sore Cream (acyclovir) topical cream 5 %
17375	Zovirax (acyclovir) eye ointment 3 %
44713	Cusiviral (acyclovir) eye ointment 3 %
44957	Super-E (d-alpha-tocopherol) oral capsule 200 internaional unit
45083	Ametop (amethocaine) topical gel 4 %
39546	amoxycillin (Bright Future) oral capsule 250 mg
41459	APT-Amoxycillin (amoxycillin (as trihydrate)) oral capsule 250 mg
59660	Blackmores Vit D3 (cholecalciferol) oral capsule 1000 international u
55341	Novorapid (insulin aspart human) subcutaneous injection, cartridge 1
05569	Trental (oxpentifylline) oral controlled-release tablet 400 mg
33470	Predfoam (prednisolone (as sodium metasulphobenzoate)) rectal foa
52336	Infloran (lactobacillus acidophilus + bifidobacterium bifidum) oral ca
52336	Infloran (lactobacillus acidophilus + bifidobacterium bifidum) oral ca
47289	Nicotinell (nicotine) buccal chewing gum (polacrilex) 2 mg (fruit)





Development on HK-wide

eHR Drug Standards

Approach Adopted

Ms S C CHIANG
Senior Pharmacist
Chief Pharmacist's Office, Hospital Authority

eHR Drug Standards

What do we want to achieve?

1	Standardisation of drug terminologies
2	Inter-operability
3	Support electronic health record
4	Pave way for future decision-support
5	Improved quality of care and patient safety

Extracted from Drug Seminar Nov 2010

In eHR, we need standardisation of drug terminologies





In 2010 - eHR to adopt SNOWMED as standard for Medication Terminology Table (MTT)

SNOMED CT (Pharmaceutical product




SNOMED-CT CONCEPT
SNOMED-CT Concept
Pharmaceutical/biologic products
Concept ID = 37383005
SNOMED-CT Concept
Substance
id=105590001
SNOMED-CT Concept
Qualifier Value
Id=362981000
Multiple product class layers
CNS Drug (Product)
ID=321087001
Multiple layers of sub-classifications (each has a concept ID)
Multiple product class layers
Anxiolytic, sedative AND/OR hypnotic (product)
ID=105917007
Substance (Substance)
Diazepam
ID=387264003
Product Category – (drug/product class)
Benzodiazepine (product)
ID=16047007
is_a
Qualifier value (Qualifier value)
Oral Tablet
ID=??????????
Product Category – (functionality)
Hypnotics
ID=321088006
is_a
has_active_ingredient
has_dose_form
Virtual therapeutic moiety (VTM)
Diazepam
ID=48546005
is_a
VTM + dosage route
is_a
Virtual medicinal product (VMP)
Diazepam 5mg Oral Tablet
ID=321197008
International Release
National Extension
is_a
is_a
is_a
Actual medicinal product (AMP)
Antenex Tablet 5mg, ID=?????
Actual medicinal product (AMP)
Diazer Tablet 5mg. ID=?????
Actual medicinal product (AMP)
Synium tablet 5mg, ID=?????



These tables and the relationships are in compliance with the SNOMED model and allows future mapping from HKMTT to SNOMED concepts.

eHR's MTT Co-Production Model with DH



The concept tables should support the co-production mechanism from DH's Drug Compendium

eHR's MTT Co-Production Model with DH



The concept tables should support the co-production mechanism from DH's Drug Compendium

eHR's MTT Co-Production Model with DH + suppliers

Medication Terminology Table





Pharmaceutical Companies / Manufacturers/ certificate holders

Product Registration

Drug name
Ingredient
Strength / concentration
Manufacturer, country…
Other registration particulars…

DoH Drug Compendium



Interface between DH-DC & MTT

HK Registration no.
Ingredient
Strength / concentration
Dosage form
etc etc…

What approach has been taken to build, develop and maintain the HKMTT for eHR?

- Standardisation of drug terminologies
- Interoperability
- Support electronic health record
- Pave way for future decision-support
- Improved quality of care and patient safety

Build, develop and maintain the HKMTT – 3 aspects

1.

HK reg	Actual Medicinal Product
51979	Ancobon (5-flucytosine) oral capsule 500 mg
41418	Acyclovir Stada (acyclovir) topical cream 5 %
47049	Zovirax Cold Sore Cream (acyclovir) topical cream 5 %
17375	Zovirax (acyclovir) eye ointment 3 %
44713	Cusiviral (acyclovir) eye ointment 3 %
44957	Super-E (d-alpha-tocopherol) oral capsule 200 internaional unit
45083	Ametop (amethocaine) topical gel 4 %
39546	amoxycillin (Bright Future) oral capsule 250 mg
41459	APT-Amoxycillin (amoxycillin (as trihydrate)) oral capsule 250 mg
59660	Blackmores Vit D3 (cholecalciferol) oral capsule 1000 international u
55341	Novorapid (insulin aspart human) subcutaneous injection, cartridge 1
05569	Trental (oxpentifylline) oral controlled-release tablet 400 mg
33470	Predfoam (prednisolone (as sodium metasulphobenzoate)) rectal foa
52336	Infloran (lactobacillus acidophilus + bifidobacterium bifidum) oral ca
52336	Infloran (lactobacillus acidophilus + bifidobacterium bifidum) oral ca
47289	Nicotinell (nicotine) buccal chewing gum (polacrilex) 2 mg (fruit)

Data Content Preparation

How, by whom and when ?

2.



Content Governance

How to ensure quality and compliance to international standards ?

3.



Building the Technical Infrastructures

What supporting technical infrastructures are required ?

HKMTT

1.

	HK reg	Actual Medicinal Product
	51979	Ancobon (5-flucytosine) oral capsule 500 mg
	41418	Acyclovir Stada (acyclovir) topical cream 5 %
	47049	Zovirax Cold Sore Cream (acyclovir) topical cream 5 %
0	17375	Zovirax (acyclovir) eye ointment 3 %
1	44713	Cusiviral (acyclovir) eye ointment 3 %
1	44957	Super-E (d-alpha-tocopherol) oral capsule 200 internaional unit
2	45083	Ametop (amethocaine) topical gel 4 %
3	39546	amoxycillin (Bright Future) oral capsule 250 mg
4	41459	APT-Amoxycillin (amoxycillin (as trihydrate)) oral capsule 250 mg
9	59660	Blackmores Vit D3 (cholecalciferol) oral capsule 1000 international u
8	55341	Novorapid (insulin aspart human) subcutaneous injection, cartridge 1
9	05569	Trental (oxpentifylline) oral controlled-release tablet 400 mg
1	33470	Predfoam (prednisolone (as sodium metasulphobenzoate)) rectal foa
4	52336	Infloran (lactobacillus acidophilus + bifidobacterium bifidum) oral ca
5	52336	Infloran (lactobacillus acidophilus + bifidobacterium bifidum) oral ca
3	47289	Nicotinell (nicotine) buccal chewing gum (polacrilex) 2 mg (fruit)

Data Content Preparation

How, by whom and when ?

Phase 1 | Phase 2 | Phase 3 | Phase 4

4-Phase Data Developmental Approach

1	Define manual co-production
	1. eHR and DH have an agreed set of critical data elements 2. DH-DC to collect essential data elements from certificate holders of registered pharmaceutical products 3. Email excel spreadsheets from DH to eHRO



Extracted from "Update on HK Drug standards – 7th DH-HA Liaison Meeting

1	**Define manual co-production**
	1. eHR and DH have an agreed set of critical data elements 2. DH-DC to collect essential data elements from certificate holders of registered pharmaceutical products 3. Email excel spreadsheets from DH to eHRO
2	**Import to MTT – initial standardisation**
	4. Import into eHR excel worksheets 5. Product data from DH will be analysed, with additional data added to compile the HKMTT concept descriptions



Extracted from "Update on HK Drug standards – 7th DH-HA Liaison Meeting

1	**Define manual co-production**
	1. eHR and DH have an agreed set of critical data elements 2. DH-DC to collect essential data elements from certificate holders of registered pharmaceutical products 3. Email excel spreadsheets from DH to eHRO
2	**Import to MTT**
	4. Import into eHR excel worksheets 5. Product data from DH will be analysed, with additional data added to compile the HKMTT concept descriptions
3	**Mapping to SNOMED-CT**
	6. Map selected MTT Product, Substance, and Qualifier concepts to SNOMED CT core concepts



Extracted from "Update on HK Drug standards – 7th DH-HA Liaison Meeting

1	**Define manual co-production**
	1. eHR and DH have an agreed set of critical data elements 2. DH-DC to collect essential data elements from certificate holders of registered pharmaceutical products 3. Email excel spreadsheets from DH to eHRO
2	**Import to MTT – initial standardisation**
	4. Import into eHR excel worksheets 5. Product data from DH will be analysed, with additional data added to compile the HKMTT concept descriptions
3	**Mapping to SNOMED-CT**
	6. Map selected MTT Product, Substance, and Qualifier concepts to SNOMED CT core concepts
4	**Full blown co-production**
	7. Development of technical interface to allow direct interface and handling of product data from DH into eHRO



Extracted from "Update on HK Drug standards – 7th DH-HA Liaison Meeting

2.



Content Governance

How to ensure quality and compliance to international standards ?

Governance Structure for HKMTT



Medication Terminology Table
Content Governance Committee

Composition of Members

Registration Body	**Drug Office, Department of Health, HKSAR Government**
HealthTerminologists	**eHR-Information Standard Office**
Doctors	**Medical Council of Hong Kong** **Dental Council of Hong Kong**
Pharmacists	**Pharmaceutical Society of Hong Kong**
Nurses	**Nursing Council of Hong Kong**
Health Informaticians	**eHR (HA-HI, HA-CPO), representatives from eHR FG (MOE App) and eHR FG (Drug Checking System)**

HKMTT Editorial Rules Contents

Section	Content	Description
1	Introduction	Foreword, background, scope, purpose and governance structure
2	HKMTT model	MTT schema design
3	HKMTT components	What is HKMTT concepts? What are the HKMTT concepts
4	Product concepts	Formal definitions Rules and style Technical specifications
5	Substance and Qualifier concepts	Formal definitions Rules and style Technical specifications
6	Appendices	General expression rules Auxiliary concepts : reference and populated list

The Design

Technical details

Series of appendices

The master layout of MTT Editorial Rules

HKMTT Editorial Rules

Purpose :
Governs how concepts are populated and maintained in MTT

To be **compiled by eHR-ISO** MTT data maintenance officer, and **endorsed by Content Governance Committee**;

Overall status :
Started since :Sep 2010

Version : **v.0.9**

Pages : **152**

Chapters : **6 chapters** completed:

1. Introduction
2. HKMTT model
3. HKMTT components
4. Product Concepts
5. Qualifier Concepts
6. Appendices (rules and populated qualifier concepts)


Hong Kong Medication Terminology Table (HKMTT)

Editorial Rules

[Draft]

Version 0.9

October 2012

HKMTT Editorial Rules Draft Version 0.9 (as of today)

MTT Editorial Rules Draft Review Mechanism



Schedule of MTT draft Editorial Rules Releases



Chapter 1 : Introduction



P. 6

1.1 Foreword

Terminologies are medical terms and concepts used to describe, classify and code the data elements and data expression languages and syntax that describe the relationships among terms/concepts [1]. They are used to record clinical information; to facilitate the storage of clinical information; to support sharing and reuse of clinical information; to support efficient query formulation; to create a natural language output from manual structured input; and to support the application of decision support algorithms [2]. Standard terminology is the foundation for supporting the development of an interoperable electronic health record (eHR) and it ensures the shared health data can be accurately interpreted, and thus can be reused to improve care delivery and optimize workflow. Standard terminology also supports disease surveillance to improve population health; generates medical knowledge to facilitate decision support and health services planning.

Example of what's in the Editorial Rules : Cited from HKCTT Editorial Policy Paper

P. 8

1.4 Development Process

The concept model design was developed and has undergone review and refinements by the eHR Information Standard Domain Group for Drug Records, with modifications in response to feedback from and consultation with members of the group, comprising of representatives from the Department of Health HKSAR, public hospitals, private hospitals, professional bodies and the eHealth Record Office.

The development of product and qualifier concepts in HKMTT has been staged into four phases:

Phase 1 : the initial concept model design, formal definition of data set and the co-production model between the Department of Health and eHealth Office
Phase 2 : preparation, verification and import of product data by the Department of Health and its import by phases into the MTT data preparation framework
Phase 3 : mapping of the initial standardization data to SNOMED-CT
Phase 4 : Technical development of the DH-CPP to MTT Co-Production Interface and the eHR Information Architecture Management System



4

The HKMTT Components

The HKMTT has conceptually been designed to encompass eight distinct "product" concepts, each containing a set of attributes, and each involves in a defined relationships (or associations, in technical point of view) with concepts (see section 5.14 for more information on MTT relationships).
As described in section 3, the 8 levels product concepts are:

- Virtual Therapeutic Moiety (VTM)
- Routed Virtual Therapeutic Moiety (VTM+Route)
- Virtual Therapeutic Moiety Routed Dose Form (VTM+Route+Form)
- Virtual Medicinal Product (VMP)
- Trade Names (TradeName)
- Routed Trade Names (TradeName+Route)
- Trade Name Routed Dose Form (TradeName+Route+Form)
- Actual Medicinal Product (AMP)

Formal definition

4.5 Virtual Medicinal Product (VMP)

4.5.1 Virtual Medicinal Product Definition

A *Virtual Medicinal Product (VMP)* is the abstract concept representing the properties of one or more clinical equivalent Trade Products (*Actual Medicinal Products (AMP)*). The VMP describes a generic product without supplier or trade name information. Equivalent AMPs are defined as those product with the same base active ingredient (with our without the salt, whichever is therapeutically significant), same strength, dose form, and adminstrable unit type (i.e. same combination of dose unit concepts associated), and being quantitatively bioequivalent.

A new VMP will be created for each different strength of a registered pharmaceutical product. If an existing generic product has a change of ingredient, such that it does not conform to the ingredients of the original VMP, then a new VMP will be created for the new product. The existing VMP may have its status changed if no bioequivalent AMP exists. In addition, all VMP concepts will have relationships to all of their active ingredients, as identified by the "has_active_ingredient" relationship.

Drug VMPs will usually follow the format of Drug Name + Route + Dose Form + Strength. Examples of VMP concepts FSNs and PTs:

Fully Specified Name	Preferred Term
cephalexin oral capsule 250 mg (product)	cephalexin oral capsule 250 mg
calcium carbonate oral chewable tablet 1 g (product)	calcium carbonate oral chewable tablet 1 g
betamethasone (as valerate) topical cream 0.1 % (product)	betamethasone (as valerate) topical cream 0.1 %
venlafaxine (as hydrochloride) oral modified-release capsule 150 mg (product)	venlafaxine (as hydrochloride) oral modified-release capsule 150 mg

Each Chapter begins with a formal definition of the concept.

Progress of briefing Editorial Rules draft with DG members

√	√	√	√
DG8 **7 MAR 2012**	**DG9** **29 MAY 2012**	**DG10** **30 AUG 2012**	**DG11** **27 NOV 2012**
The design Introduction to MTT Concept model components	**Technical details of concept creation in MTT** How **HK Product** concepts are created	**Technical details of concept creation in MTT** How **Qualifiers** concepts are created	**Specific editorial rules** Capitalisation rules Ingredient naming conventions Strength expression rules **Qualifier tables** Population methods and examples

Each Chapter begins with a formal definition of the concept.

3.



Building the Technical Infrastructures

What supporting technical infrastructures are required ?

1	**Define manual co-production**
	1. eHR and DH have an agreed set of critical data elements 2. DH-DC to collect essential data elements from certificate holders of registered pharmaceutical products 3. Email excel spreadsheets from DH to eHRO
2	**Import to MTT – initial standardisation**
	4. Import into eHR excel worksheets 5. Product data from DH will be analysed, with additional data added to compile the HKMTT concept descriptions
3	**Mapping to SNOMED-CT**
	6. Map selected MTT Product, Substance, and Qualifier concepts to SNOMED CT core concepts
4	**Full blown co-production**
	7. Development of technical interface to allow direct interface and handling of product data from DH into eHRO



Extracted from "Update on HK Drug standards – 7th DH-HA Liaison Meeting



The scope of eHR MTT table is to maintain standardised terminology to cover all Hong Kong registered pharmaceutical products.



In eHR Office, a terminology database is being developed to maintain all HKMTT and its mapping data to SNOMED CT.



The Data Interface of Registered Pharmaceutical Products (DiRPP) is being built as a direct data channel from DH to eHR Information Standard Office. The data received at eHR Office will be sent into a concept submission page ("the InBox") of the **Information Architecture Management System (eHR-IAMS)**



IAMS provides data maintenance facility for the Pharmacist to import the Pharmaceutical Product data into MTT, and data maintenance in adherence to the MTT Editorial Rules.

HKMTT Product Hierarchy



Editorials and carefully pre-defined system logics are implemented into the system which helps to automate the building of MTT concept, maintaining their defining attributes and relationships building.



MTT concepts in eHR-IAMS will also be mapped to SNOMED CT core in Phase 3 of the data preparation process.



The ultimate aim of MTT data is to provide standard drug terminologies for eHR Medication record (Prescribing & Dispensing) sharing

What approach has been taken to build, develop and maintain the HKMTT for eHR?

- Standardisation of drug terminologies
- Interoperability
- Support electronic health record
- Pave way for future decision-support
- Improved quality of care and patient safety

Practical Usage of MTT

Medication Terminology Table

Data elements for Clinical Systems

Virtual Therapeutic Moiety
diazepam

VTM + Route
diazepam oral

VMT + Route + Dose Form
diazepam oral tablet

Virtual Medicinal Product
diazepam oral tablet 5 mg



Provides a logical hierarchies for prescribing drug search and other structural elements
(e.g. drug-based prescribing unit)

Trade Name
Diazer 5 (diazepam)

TN + Route
Diazer 5 (diazepam) oral

TN +Route + Dose Form
Diazer 5 (diazepam) oral tablet

Actual Medicinal Product
Diazer 5 (diazepam) oral tablet 5 mg

Product Safety

diazepam
oral
tablet
5 mg
diazepam
oral
tablet
5 mg
Diazer 5
HK-50904

HK Registration no.	Trade Name	Virtual Therapeutic Moiety (preferred term)	Route	Dose Form	Strength
50904	Diazer 5	diazepam	oral	tablet	5 mg


eHR Drug Record
Medication Vocabulary Table
Virtual Therapeutic Moiety (VTM)
VTM conceptID
diazepam
Tradename (TN)
TN conceptID
Diazer 5 (diazepam)
IS_A
IS_A
VTM+R
VTM+R conceptID
diazepam oral
TN+Route
TN+R conceptID
Diazer 5 (diazepam) oral
IS_A
IS_A
VTM+R+F
Route VTM+R+F conceptID
diazepam oral tablet
TN+Route+Form
TN+R+F conceptID
Diazer 5 (diazepam) oral tablet
IS_A
IS_A
virtual medicinal product
VMP conceptID
diazepam oral tablet 5 mg
actual medicinal product
AMP conceptID
Diazer 5 (diazepam) oral tablet 5 mg
HK - 50904
MTT conceptIDs acquired via HK-Reg
VTM
TN
VTM+R
TN+R
VTM+R+F
TN+R+F
VMP
AMP
Diazer 5 tab
HK-50904
mapping
Healthcare Providers Drug information database
醫健通 ehealth


eHR Drug Record
Patient is allergic to "diazepam"
MVT conceptIDs acquired via HK-Reg
VTM
TN
VTM+R
TN+R
VTM+R+F
TN+R+F
VMP
AMP
Diazer 5 tab
HK-50904
Healthcare Providers Drug information database
mapping
Medication Vocabulary Table
Virtual Therapeutic Moiety (VTM)
VTM conceptID
diazepam
Tradename (TN)
TN conceptID
Diazer 5 (diazepam)
IS_A
VTM+R
VTM+R conceptID
diazepam oral
TN+Route
TN+R conceptID
Diazer 5 (diazepam) oral
VTM+R+F
Route VTM+R+F conceptID
diazepam oral tablet
TN+Route+Form
TN+R+F conceptID
Diazer 5 (diazepam) oral tablet
virtual medicinal product
VMP conceptID
diazepam oral tablet 5 mg
actual medicinal product
AMP conceptID
Diazer 5 (diazepam) oral tablet 5 mg
HK - 50904


eHR Drug Record
Patient is allergic to "diazepam"
Dr prescribed "diazepam oral tablet"
MVT conceptIDs acquired via HK-Reg
VTM
TN
VTM+R
TN+R
VTM+R+F
TN+R+F
VMP
AMP
Diazer 5 tab
HK-50904
Healthcare Providers Drug information database
mapping
Medication Vocabulary Table
Virtual Therapeutic Moiety (VTM)
VTM conceptID
diazepam
Tradename (TN)
TN conceptID
Diazer 5 (diazepam)
IS_A
VTM+R
VTM+R conceptID
diazepam oral
TN+Route
TN+R conceptID
Diazer 5 (diazepam) oral
VTM+R+F
Route VTM+R+F conceptID
diazepam oral tablet
TN+Route+Form
TN+R+F conceptID
Diazer 5 (diazepam) oral tablet
virtual medicinal product
VMP conceptID
diazepam oral tablet 5 mg
actual medicinal product
AMP conceptID
Diazer 5 (diazepam) oral tablet 5 mg
HK - 50904


eHR Drug Record
Patient is allergic to "diazepam"
Dr prescribed "diazepam oral tablet"
Pharmacy dispensed "Diazer (diazepam) oral tablet 5 mg"
MTT conceptIDs acquired via HK-Reg
VTM
TN
VTM+R
TN+R
VTM+R+F
TN+R+F
VMP
AMP
Diazer 5 tab
HK-50904
Healthcare Providers Drug information database
mapping
Medication Vocabulary Table
Virtual Therapeutic Moiety (VTM)
VTM conceptID
diazepam
Tradename (TN)
TN conceptID
Diazer 5 (diazepam)
IS_A
VTM+R
VTM+R conceptID
diazepam oral
TN+Route
TN+R conceptID
Diazer 5 (diazepam) oral
VTM+R+F
Route VTM+R+F conceptID
diazepam oral tablet
TN+Route+Form
TN+R+F conceptID
Diazer 5 (diazepam) oral tablet
virtual medicinal product
VMP conceptID
diazepam oral tablet 5 mg
actual medicinal product
AMP conceptID
Diazer 5 (diazepam) oral tablet 5 mg
HK - 50904

Supporting local Interoperability & drug record sharing between different systems / service providers



Participating organisations will need to map to the MTT tables according to their drug data table structure. This mapping allows communication with eHR.



Full interoperability

Level 3

Data-service

Regular data update by eHR Office.

eHR Applications
(MOE OnRamp, CMS Adaptation, Structured Alert Adaptation Module)

Level 3

eHR Drug Record

Coded information, full / partial interoperability

Local drug information database

Map local data to MTT concepts

Data-service

User to obtain MTT data via HKCTT Download Centre

HKMTT is provided in 2 Data Service modes : (i) direct adaptation of eHR Applications (which has all medication-related functions supported by MTT); or (ii) by subscribing and maintaining the MTT data content via HKCTT Data download and mapping to local drug information.

Future Usage of MTT

Medication Terminology Table

Medication Decision Support

Virtual Therapeutic Moiety
diazepam

Trade Name
Diazer 5 (diazepam)

Allergy documentation and Checking

VTM + Route
diazepam oral

TN + Route
Diazer 5 (diazepam) oral

Drug-Drug Interaction
G6PD / Pregnancy checking
Drug Duplication Checking

VMT + Route + Dose Form
diazepam oral tablet

TN +Route + Dose Form
Diazer 5 (diazepam) oral tablet

diazepam oral tablet

diazepam oral tablet Diazer 5

Virtual Medicinal Product
diazepam oral tablet 5 mg

Actual Medicinal Product
Diazer 5 (diazepam) oral tablet 5 mg

Dosage Range Checking

diazepam oral tablet 5 mg

diazepam oral tablet 5 mg Diazer 5 HK-50904

HK Registration no.	Trade Name	Virtual Therapeutic Moiety (preferred term)	Route	Dose Form	Strength
50904	Diazer 5	diazepam	oral	tablet	5 mg

Summary

What approach has been taken to build, develop and maintain the HKMTT for eHR?

- **Collaborative approach**
- **Standandised approach**
- **Interoperable approach**
- **Sharable data approach**
- **Better patient and medication safety approach**
- **Timely approach**